City Therapeutics Inc.
CTY | NASDAQ
$20.66
-$0.05 (-0.24%)
Nov 2, 2026, 11:01 AM ET · Market open
Fiscal Year Period Ending | FY 2019 Dec 31, 2019 | FY 2018 Dec 31, 2018 | FY 2017 Dec 31, 2017 | FY 2016 Dec 31, 2016 | FY 2015 Dec 31, 2015 | FY 2014 Dec 31, 2014 |
|---|---|---|---|---|---|---|
Revenue | 8.16B | 8.49B | 8.55B | 8.91B | 8.96B | 8.84B |
Cost of Revenue | 2.44B | 2.77B | 2.88B | 2.93B | 2.87B | 2.88B |
Gross Profit | 5.72B | 5.73B | 5.67B | 5.98B | 6.09B | 5.96B |
Operating Income | 2.88B | 2.66B | 2.31B | 2.32B | 2.26B | 2.11B |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | 2.47B | 2.16B | 1.79B | 1.76B | 1.73B | 1.61B |
Net Income | 1.83B | 1.67B | 1.66B | 1.09B | 1.07B | 970M |
Selling & General & Admin | 659M | 799M | 925M | 1.02B | 1.02B | 1.09B |
Research & Development | n/a | n/a | n/a | n/a | n/a | n/a |
Other Expenses | n/a | 5.03B | 5.31B | 5.57B | 5.69B | 5.64B |
Operating Expenses | 659M | 5.83B | 6.24B | 6.59B | 6.7B | 6.73B |
Interest Expense | n/a | 448M | 465M | 478M | 473M | 464M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 5.27B | 8.6B | 9.12B | 9.52B | 9.58B | 9.61B |
Income Tax Expense | 641M | 494M | 134M | 678M | 659M | 639M |
Shares Outstanding (Basic) | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Diluted) | n/a | n/a | n/a | n/a | n/a | n/a |
EPS (Basic) | n/a | n/a | n/a | n/a | n/a | n/a |
EPS (Diluted) | n/a | n/a | n/a | n/a | n/a | n/a |
EBITDA | 3.83B | 4.04B | 3.84B | 3.92B | 4.05B | 4.04B |
EBIT | n/a | 2.61B | 2.26B | 2.24B | 2.21B | 2.07B |
Depreciation & Amortization | 1.36B | 1.44B | 1.58B | 1.68B | 1.84B | 1.97B |
Add to Watchlist
Select watchlists to add or remove CTY